Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp.


Journal Article

Acinetobacter sp. isolates having multidrug resistance (MDR) patterns have become common in many medical centers worldwide, limiting therapeutic options. A five-center study tested 103 contemporary clinical Acinetobacter spp., including MDR strains, by reference broth microdilution and disk diffusion (15-mug disk content) methods against tigecycline. Applying U.S. Food and Drug Administration tigecycline breakpoint criteria for Enterobacteriaceae (susceptibility at < or =2 microg/ml [< or =1 microg/ml by the European Committee on Antimicrobial Susceptibility Testing]; disk diffusion breakpoints at > or =19 mm and < or =14 mm) to Acinetobacter spp. led to an unacceptable error rate (23.3%). However, an adjustment of tigecycline disk diffusion breakpoints (susceptible/resistant) to > or =16/ < or =12 mm reduced intermethod errors to an acceptable level (only 9.7%, all minor).

Full Text

Duke Authors

Cited Authors

  • Jones, RN; Ferraro, MJ; Reller, LB; Schreckenberger, PC; Swenson, JM; Sader, HS

Published Date

  • January 1, 2007

Published In

Volume / Issue

  • 45 / 1

Start / End Page

  • 227 - 230

PubMed ID

  • 17093026

Pubmed Central ID

  • 17093026

International Standard Serial Number (ISSN)

  • 0095-1137

Digital Object Identifier (DOI)

  • 10.1128/JCM.01588-06


  • eng

Conference Location

  • United States